AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUL 161 min read$MLYS

Rodman David Malcom sold $557K of MLYS

Rodman David Malcom (Chief Medical Officer) sold 20,407 shares of Mineralys Therapeutics, Inc. (MLYS) at an average of $27.28 ($26.61–$27.58, $0.56M total) across 2 trades over 2026-07-13 to 2026-07-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Rodman David Malcom
Published Jul 16, 2026, 12:58 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 16, 2026, 1:00 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$MLYS
Neutral
high confidence
Mentioned
$MLYS
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MLYSNeutralLow
01

Why it matters

The newest fact is the disclosed sale size, dates, and weighted-average prices for the CMO’s open-market trades under a 10b5-1 plan.

02

Market read

Traders may monitor insider activity for sentiment, but this filing alone does not change fundamentals or near-term expectations.

03

What to watch

Insider sales can be misread; traders should compare with prior Form 4 patterns and whether any concurrent news (financing, trial updates) is present, which is not included here.

Relevance 4/10Novelty 3/10Timing: as-of the July 15 after-hours Form 4 filing date

Background

The article is a SEC Form 4 insider transaction disclosure for Mineralys Therapeutics, Inc.

Company-level read

Ticker impact

$MLYSNeutralHigh confidence
Context

Rodman David Malcom, Mineralys Therapeutics CMO, sold $556,671 of MLYS shares in two open-market trades under a 10b5-1 plan.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and typically short-lived.

Evidence & confidence

The filing is a routine Form 4 open-market sale by an officer with an existing 10b5-1 plan, and it provides no new company fundamentals or guidance.

Market effects

Sector

No direct sector read-through; this is company-specific insider transaction data.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect liquidity planning rather than bearish expectations.

Key entities

  • issuer
    Mineralys Therapeutics, Inc.

    Subject of the Form 4 insider sale disclosure (MLYS).

  • insider
    Rodman David Malcom

    Chief Medical Officer who executed the open-market sale(s).

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

MLYS insider trading history →

Related articles

OCT 12
$MLYSHigh

H.C. Wainwright reiterates Mineralys stock rating on new data

H.C. Wainwright reiterated a Buy rating and $56.00 price target for Mineralys Therapeutics (NASDAQ:MLYS), citing new clinical data for lorundrostat. The target implies 140% upside from the current stock price of $23.37. The firm highlights the drug's potential in treating difficult-to-treat hypertension ahead of a December 2026 PDUFA date. Mineralys reported a wider-than-expected Q2 2026 loss of $2.85 per share. UBS initiated coverage with a Neutral rating and $29.00 price target.

investing.com2 min
OCT 9
$MLYSHighAI 9/10

Mineralys Therapeutics Presents New Data for Lorundrostat at the American Heart Association Hypertension Scientific Sessions 2026

Mineralys Therapeutics (MLYS) presented data at the American Heart Association Hypertension Scientific Sessions 2026. In the Launch-HTN trial, 46% of participants with difficult-to-treat hypertension achieved the AHA/ACC systolic blood pressure target of <130 mmHg with lorundrostat 50 mg. In the Explore-OSA trial, lorundrostat reduced morning systolic blood pressure by 11.1 mmHg at Week 4. Both trials showed favorable safety and tolerability profiles for lorundrostat.

globenewswire.com2 min
AUG 22
$MLYSMed

Why Mineralys Therapeutics (MLYS) Is Getting Fresh Attention

Mineralys Therapeutics (MLYS) reported a Q2 2026 net loss of $241.07M. The company appointed James J. Ferguson III, M.D., as Chief Medical Officer. Shares are down 5.04% in 30 days and 14.07% in 90 days, but up 72.32% in 1 year and 97.31% in 3 years. Analysts suggest fair value at $50.88, above the current $25.65, based on lorundrostat's potential. Risks include regulatory outcomes and cash burn.

simplywall.st2 min
AUG 19
$MLYSMed

Mineralys (MLYS) Q2 2026 Earnings Call Transcript

Mineralys Therapeutics (MLYS) reported Q2 2026 earnings, highlighting a net loss of $241.1 million due to royalty repurchase obligations. Key financial activities included a $150 million equity offering and a $100 million tranche from a $500 million loan. The company is preparing for the FDA's PDUFA date for lorundrostat, a hypertension treatment, with commercial launch plans and payer discussions underway. Management expressed optimism about the regulatory review and market potential.

fool.com4 min
AUG 13
$MLYSMed

Mineralys Therapeutics, Inc. Q2 2026 Earnings Call Summary

Mineralys Therapeutics reported Q2 2026 updates on lorundrostat. The company said it repurchased future royalties from Mitsubishi Tanabe for $200 million, secured a $500 million senior secured term loan, and completed a $150 million equity offering. R&D rose to $221.4 million. It cited LAUNCH-HTN results and targeted a Dec. 22, 2026 PDUFA, with FDA discussions in Oct-Nov 2026.

yahoo.com7 min